Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Nivolumab shows modest antitumour activity in advanced adrenocortical carcinoma

19 Dec 2019

Patients with metastatic adrenocortical carcinoma (ACC) appear to achieve modest benefits from treatment with nivolumab, as shown by results of a phase II trial. The safety profile of nivolumab is consistent with previous clinical experience with no unforeseen adverse events (AEs).

Ten patients with advanced ACC were included in the study between March and December 2016. They were administered a median of two doses of nivolumab. Three patients received only one treatment: one died of disease progression, one stopped due to AEs, and one withdrew after treatment initiation.

Over a median follow-up of 4.5 months (range, 0.1–25.6 months), two patients achieved stable disease for 48 and 11 weeks, respectively, and one patient had an unconfirmed partial response but discontinued the study due to an AE.

Majority of the AEs were mild (grade 1/2). Grade 3/4 treatment-related AEs were also reported, including mucositis, odynophagia, and aspartate aminotransferase and alanine aminotransferase elevations.

This single-arm, multicentre, phase II clinical trial with two-stage design conducted in a comprehensive cancer centre enrolled 10 adult patients with metastatic ACC previously treated with platinum-based chemotherapy or mitotane and those who declined front-line chemotherapy. Patients received nivolumab 240 mg intravenously every 2 weeks.

Objective response rate according to the response evaluation criteria in solid tumours was the primary endpoint. Progression-free survival, overall survival and safety were the secondary endpoints.

“Systemic treatment of metastatic ACC remains limited to chemotherapy and mitotane,” the authors said. “Preliminary evidence suggesting that antitumour immune responses can be elicited in ACC has fostered interest in checkpoint inhibitors such as anti–PD-1 nivolumab.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.